Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af topisk anvendelse af BMX-010 hos personer med rosacea

15. oktober 2026 opdateret af: BioMimetix JV, LLC

Et eksplorativt forsøg til evaluering af den kliniske effektivitet af en topisk anvendelse af BMX-010 hos personer med rosacea

This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part.

Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part.

In both parts, adult subjects with Rosacea will be enrolled.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

6

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Colorado
      • Englewood, Colorado, Forenede Stater, 80113
        • Colorado Skin Care

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female, at least 18 years of age;
  2. A clinical diagnosis of mild to severe facial rosacea;
  3. Screening and Baseline IGA score > 2 (greater than or equal to 2);
  4. A minimum Clinician Erythema Assessment (CEA) score of 2 at Screening and at Baseline Visits (prior to the investigational product application);
  5. Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
  6. Candidate for topical treatment of Rosacea;
  7. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup;
  8. Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
  9. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
  10. Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
  11. Ability to understand and provide written informed consent.

Exclusion Criteria:

  1. Any dermatological conditions on the face that could interfere with clinical evaluations;
  2. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
  3. Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
  4. Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
  5. Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
  6. Use of medicated make-up (including anti-aging make-up) throughout the study;
  7. Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
  8. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
  9. Use of medicated cleansers on the face (throughout the study);
  10. Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
  11. Systemic or skin infection requiring antimicrobial therapy;
  12. Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
  13. Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
  14. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
  15. Active drug or alcohol dependence;
  16. Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
  17. Previous clinical trial participation for the indication being treated in this protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: BMX-010 0.03%

Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.

Safety and efficacy of BMX-010 in topical treatment of rosacea.

Eksperimentel: BMX-010 0.1%

Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.

Safety and efficacy of BMX-010 in topical treatment of rosacea.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Treatment Success Rate
Tidsramme: 43 days

The percentage of subjects will be reported that experience a clinically meaningful treatment success, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade from the baseline assessment prior to treatment to the final assessment two weeks after dosing ends (Day 43).

43 days
Clinical Erythema Assessment (CEA): Clinically Meaningful Erythema Reduction Rate
Tidsramme: 43 days

Assessed by number of participants with at least a 2-point reduction in Clinical Erythema Assessment (CEA) grade from the baseline score prior to treatment to a final assessment two weeks after dosing ends (Day 43).

43 days
Investigator Global Assessment (IGA) Grade: Rosacea Severity Change Over Treatment Period
Tidsramme: 28 days

The Investigator Global Assessment (IGA) grade, which will be assessed weekly, is a clinical assessment of disease severity. Scores range from 0 (clear) - 4 (severe). The change in IGA score from Baseline to 28 days of treatment will be reported.

28 days
Clinical Erythema Assessment (CEA): Erythema Severity Change Over Treatment Period
Tidsramme: 28 days

The Clinical Erythema Assessment (CEA) grade will be assessed weekly. Grades range from 0 = clear/no erythema to 4 = severe/fiery red erythema. The change in CEA score from Baseline to 28 days of treatment will be reported.

28 days
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Reduction During Treatment
Tidsramme: 28 days

The percentage of subjects will be reported that experience a clinically meaningful rosacea reduction, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade over the treatment period of 28 days.

28 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Photography Documenting Rosacea Symptoms in Patients Treated With BMX-010
Tidsramme: 43 days

If consented by the patient, photos will be taken at each study visit. The number of patients photographed will be reported.

43 days
Change in Number of Inflammatory Papules/Pustules From Baseline to 43 Day Follow-up.
Tidsramme: 43 days

Inflammatory lesions will be counted at each study visit. The mean percent change in inflammatory papules/pustules counts from baseline to the final (day 43) follow-up will be reported.

43 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. februar 2019

Primær færdiggørelse (Faktiske)

2. juli 2019

Studieafslutning (Faktiske)

13. februar 2023

Datoer for studieregistrering

Først indsendt

15. november 2018

Først indsendt, der opfyldte QC-kriterier

26. november 2018

Først opslået (Faktiske)

28. november 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • BMX-DERM-202

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .